Respiratory Inhalers - Market Insights, Competitive Landscape, and Market Forecast - 2030

Respiratory Inhalers Market by Product Type (Dry Powder Inhaler, Metred Dose Inhaler, Soft Mist Inhaler, and Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, and Compressor Nebulizers]), Type (Conventional Inhaler Devices and Smart Inhaler Devices), Patient Type (Adult and Paediatrics), Indication (Asthma, COPD, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of respiratory disorders and rise in pollution levels worldwide

The respiratory inhalers market was valued at USD 30,267.49 million in 2023 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 40,540.87 million by 2030. The respiratory inhalers market is experiencing significant growth due to the rising prevalence of respiratory conditions such as asthma & chronic obstructive pulmonary disease (COPD), coupled with advancements in technology, growing smartphone adoption, and the increasing awareness of smart health solutions, which are acting as major factors driving the substantial demand for respiratory inhalers from 2024 to 2030.

Respiratory Inhalers Market Dynamics:

According to data provided by the World Health Organization (2024), in 2019 there were 262 million people affected by asthma. As per the same source in 2023, 392 million people were living with COPD with three-quarters of them living in low and middle-income countries. Respiratory inhalers play a crucial role in managing both asthma and COPD. For asthma patients, respiratory inhalers are essential for delivering quick relief during an attack and for maintaining long-term control to prevent exacerbations. In COPD, inhalers are used to alleviate symptoms such as breathlessness and to improve overall lung function, particularly in patients with more severe forms of the disease.

The rising global urbanization led to a steady increase in respiratory illness owing to increasing pollution, and a rise in the adoption of sedentary lifestyles such as smoking which also leads to second-hand inhalation, which may also contribute to the market growth for respiratory inhalers. The WHO in 2022 stated that in 2019, 99% of the global population resided in areas where air quality did not meet the WHO's guidelines. Respiratory inhalers are instrumental in managing respiratory conditions by enabling real-time monitoring and delivering personalized feedback, thereby improving adherence to treatment protocols. Their integration with digital health platforms addresses challenges from adverse air quality and lifestyle factors, optimizing respiratory health management.

Hence, the interplay of all the above-mentioned factors is expected to drive the respiratory inhalers market during the given forecast period from 2024 to 2030.

However, the availability of alternative therapies, inhaled corticosteroids associated with oral thrush and fungal infections, among others may restrict the market growth for the respiratory inhalers market.

Respiratory Inhalers Market Segment Analysis:

Respiratory Inhalers Market by Product Type (Dry Powder Inhaler, Metred Dose Inhaler, Soft Mist Inhaler, and Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, and Compressor Nebulizers]), Type (Conventional Inhaler Devices and Smart Inhaler Devices), Patient Type (Adult and Paediatrics), Indication (Asthma, COPD, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the respiratory inhalers market, the metered dose inhaler (MDI) category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category can be attributed to the various features and applications of the MDI category.

MDIs are equipped with integrated sensors that track medication usage and monitor inhalation techniques, ensuring accurate and consistent delivery of medication. They often include real-time feedback mechanisms that alert users if they are not using the device correctly, thereby improving adherence to prescribed treatments.

Additionally, smart MDIs connect to mobile apps or digital health platforms, providing users with detailed insights into their medication patterns, symptom progression, and environmental triggers. This data can be shared with healthcare providers to facilitate personalized treatment adjustments and better disease management. Enhanced features such as dose reminders, usage tracking, and connectivity with other health devices further support comprehensive respiratory care and contribute to improved patient outcomes.

Therefore, owing to the above-mentioned factors, the demand for the MDI category upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the respiratory inhalers market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall respiratory inhalers market:

Among all the regions, North America is estimated to hold a significant revenue share in the respiratory inhalers market. This is driven by the increasing prevalence of chronic respiratory diseases and the need for improved management tools. Advancement in respiratory inhalers technology, regulatory support, and the introduction of innovative devices by key market players are anticipated to significantly propel market growth for respiratory inhalers in North America from 2024 to 2030.

According to data from the Centers for Disease Control and Prevention (2023), in 2021, approximately 11.5% of US adults aged 18 years or older were current cigarette smokers, equating to an estimated 28.3 million individuals. As per the same source, over 16 million Americans are affected by smoking-related diseases. Smoking is a major risk factor associated with the development of COPD disorder among the population.

As per data from the American Lung Association data updated in April 2024, stated that more than 34 million people are currently living in the US with chronic lung diseases like asthma and COPD. In addition to this, the same source stated that in 2023, approximately 11.7 million people in the US were living with chronic respiratory disorders, which over time makes it harder for patients to breathe. Furthermore, as per the data provided by the CDC (2023), in 2021, around 14.2 million people in the US had COPD.

Respiratory inhalers are vital in managing chronic lung diseases like asthma and COPD by delivering medication directly to the lungs, providing quick symptom relief, and helping improve respiratory function. They are essential for both immediate treatment during flare-ups and long-term control, enhancing the quality of life for those with respiratory conditions.

Various product developmental strategies such as clearances in the region by regulatory authorities in the region play a major role in pushing forward the revenue shares of respiratory inhalers in the region. For example, in June 2023 Huma received U.S. Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software as a Medical Device (SaMD) platform. The platform's device-agnostic nature enables it to integrate with external third-party devices, such as heart rate and blood sugar monitors, as well as smart inhalers, thereby expanding its functionality and versatility.

Moreover, the constant focus of market players in targeting the region in product launches is further expected to propel the growth of the North American respiratory inhalers market. For example in June 2024, Aseptika launched PUFF Clicker3, a respiratory smart inhaler dose tracker that is compatible with pressurized metered dose inhalers (pMDI) and dry powder inhalers (DPI).

Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the respiratory inhalers market during the forecast period from 2024 to 2030.

Respiratory Inhalers Market key players:

Some of the key market players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A., Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd, Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, HONSUN, and others.

Recent Developmental Activities in the Respiratory Inhalers Market:

• In August 2022, Aptar Pharma acquired the rights for Orbital dry powder inhaler. The company had acquired the worldwide rights to clinical stage drug developer Pharmaxis Orbital Inhaler, a device that had been designed to deliver high payload dry powder to the lungs.
• In February 2022, Honeywell Teams announced about their collaboration with Astrazeneca that were involved in the development of next- generation respiratory inhalers that use the near-zero global warming potential propellant.
• In October 2021, BreatheSuite announced that it received 510(k) clearance from the FDA for its metered dose inhaler V1 device that is capable of turning the existing inhalers into smart inhalers for people suffering from asthma and COPD.

Key takeaways from the Respiratory Inhalers market report study

• Market size analysis for current respiratory inhalers market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the respiratory inhalers market
• Various opportunities available for the other competitors in the respiratory inhalers market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current respiratory inhalers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for respiratory inhalers market growth in the coming future?

Target audience who can be benefited from this Respiratory Inhalers market report study

• Respiratory inhalers device providers
• Research organizations and consulting companies
• Respiratory inhalers related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in respiratory inhalers
• Various end-users who want to know more about the respiratory inhalers market and the latest developments in the respiratory inhalers market

Frequently Asked Questions for the Respiratory Inhalers Market:

1. What are Respiratory Inhalers?

The respiratory inhalers are portable devices used to deliver medications for chronic obstructive pulmonary disease (COPD) and asthma into the airways. They are used to prevent and treat exacerbations of these chronic conditions. They offer the advantage of avoiding the systemic effects of drugs while ensuring that drugs are delivered right where they are needed.

2. What is the market for Respiratory Inhalers?

The respiratory inhalers market was valued at USD 30,267.49 million in 2023 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 40,540.87 million by 2030.

3. What are the drivers for the Respiratory Inhalers market?

The respiratory inhalers market is experiencing significant growth due to the rising prevalence of respiratory conditions such as asthma & chronic obstructive pulmonary disease (COPD), coupled with advancements in technology, growing smartphone adoption, and the increasing awareness of smart health solutions, which are acting as major factors driving the substantial demand for respiratory inhalers from 2024 to 2030.

4. Who are the key players operating in the Respiratory Inhalers market?

Some of the major market key players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A., Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd, Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, HONSUN, and others.

5. Which region has the highest share in the Respiratory Inhalers market?

Among all the regions, North America is estimated to hold a significant revenue share in the respiratory inhalers market. This is driven by the increasing prevalence of chronic respiratory diseases and the need for improved management tools. Advancement in respiratory inhaler technology, regulatory support, and the introduction of innovative devices by key market players are anticipated to significantly propel market growth for respiratory inhalers in North America from 2024 to 2030.